Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine …

RZ Mahfouz, A Jankowska, Q Ebrahem, X Gu… - Clinical cancer …, 2013 - AACR
Purpose: The cytidine analogs 5-azacytidine and decitabine, used to treat myelodysplastic
syndromes (MDS), produce a molecular epigenetic effect, depletion of DNA …
被引用次数：143 相关文章

Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or …

RZ Mahfouz, A Jankowska, Q Ebrahem, X Gu… - Clinical Cancer …, 2013 - cir.nii.ac.jp
< jats: title> Abstract</jats: title>< jats: p> Purpose: The cytidine analogs 5-azacytidine and
decitabine, used to treat myelodysplastic syndromes (MDS), produce a molecular epigenetic …

Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine …

RZ Mahfouz, A Jankowska… - … : an official journal …, 2013 - pubmed.ncbi.nlm.nih.gov
Purpose The cytidine analogs 5-azacytidine and decitabine, used to treat myelodysplastic
syndromes (MDS), produce a molecular epigenetic effect, depletion of DNA …

Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or …

RZ Mahfouz, A Jankowska, Q Ebrahem… - Clinical cancer …, 2013 - scholarship.miami.edu
Purpose: The cytidine analogs 5-azacytidine and decitabine, used to treat myelodysplastic
syndromes (MDS), produce a molecular epigenetic effect, depletion of DNA …

Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine …

RZ Mahfouz, A Jankowska, Q Ebrahem… - … Cancer Research: an …, 2013 - europepmc.org
Purpose The cytidine analogs 5-azacytidine and decitabine, used to treat myelodysplastic
syndromes (MDS), produce a molecular epigenetic effect, depletion of DNA …
[HTML] nih.gov

[HTML][HTML] Increased CDA expression/activity in males contributes to decreased cytidine analogue half-life and likely contributes to worse outcomes with 5-azacytidine or …

RZ Mahfouz, A Jankowska, Q Ebrahem… - … cancer research: an …, 2013 - ncbi.nlm.nih.gov
Purpose The cytidine analogues 5-azacytidine and decitabine, used to treat myelodysplastic
syndromes (MDS), produce a molecular epigenetic effect, depletion of DNA …
[PDF] academia.edu

[PDF][PDF] Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine …

RZ Mahfouz, A Jankowska, Q Ebrahem, X Gu… - Clin Cancer …, 2013 - academia.edu
Purpose: The cytidine analogs 5-azacytidine and decitabine, used to treat myelodysplastic
syndromes (MDS), produce a molecular epigenetic effect, depletion of DNA …

[引用][C] Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine …

RZ MAHFOUZ, A JANKOWSKA… - Clinical cancer …, 2013 - pascal-francis.inist.fr
Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life
and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy CNRS …

Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine …

RZ Mahfouz, A Jankowska, Q Ebrahem… - … Cancer Research: an …, 2013 - europepmc.org
Purpose The cytidine analogs 5-azacytidine and decitabine, used to treat myelodysplastic
syndromes (MDS), produce a molecular epigenetic effect, depletion of DNA …